Tislelizumab for treating non-small-cell lung cancer, oesophageal squamous cell carcinoma, and nasopharyngeal carcinoma

Published on 01 Aug 2025
Last Updated on 01 Aug 2025

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:

• Tislelizumab 100 mg/10 mL concentrate for solution for infusion for the following indications:

  • in combination with platinum-doublet chemotherapy for untreated locally advanced or metastatic squamous non-small-cell lung cancer (NSCLC);

  • treatment of patients with locally advanced or metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy;

  • in combination with platinum-based chemotherapy for untreated, unresectable, locally advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC);

  • in combination with platinum-based chemotherapy for untreated, unresectable, locally advanced, recurrent or metastatic OSCC; and

  • in combination with chemotherapy for first-line systemic treatment of recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma.

in view of acceptable clinical effectiveness and safety, an acceptable pricing proposal by the company, and potential cost savings to the healthcare system.

Funding status

Tislelizumab 100 mg/10 mL concentrate for solution for infusion is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications from 1 September 2025.

Clinical indications, subsidy class and MediShield Life claim limits for tislelizumab are provided in the Annex.

Tislelizumab for treating non-small-cell lung cancer, oesophageal squamous cell carcinoma, and nasopharyngeal carcinoma [PDF, 130 KB]